Tengyi Wang

Tengyi Wang

Auto-generated profile, based on publicly available information

Tengyi Wang

School of Public Health, Harbin Medical University, Harbin, China

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 November 2023 in JMIR Medical Informatics
Verified
Journal Article
Open access
JYJiancheng Ye
Jiancheng Ye
SXShangzhi Xiong
Shangzhi Xiong
TWTengyi Wang
Tengyi Wang
JLJingyi Li
Jingyi Li
NCNan Cheng
Nan Cheng
YYYang Yang
Yang Yang
Background: Clinical trials are a crucial element in advancing medical knowledge and developing new treatments by establishing the evidence base for safety and therapeutic efficacy. However, the success of these trials depends on various factors, including trial design, project planning, research staff training, and adequate sample size. It is also crucial to recruit participants efficiently and retain them throughout the trial to ensure timely completion. Objective: There is an increasing interest in using electronic health records (EHRs)—a widely adopted tool in clinical practice—for clinical trials. This scoping review aims to understand the use of EHR in supporting the conduct of clinical trials in low- and middle-income countries (LMICs) and to identify its strengths and limitations. Methods: A comprehensive search was performed using 5 databases: MEDLINE, Embase, Scopus, Cochrane Library, and the Cumulative Index to Nursing and Allied Health Literature. We followed the latest version of the PRISMA-ScR (Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews) guideline to conduct this review. We included clinical trials that used EHR at any step, conducted a narrative synthesis of the included studies, and mapped the roles of EHRs into the life cycle of a clinical trial. Results: A total of 30 studies met the inclusion criteria: 13 were randomized controlled trials, 3 were cluster randomized controlled trials, 12 were quasi-experimental studies, and 2 were feasibility pilot studies. Most of the studies addressed infectious diseases (15/30, 50%), with 80% (12/15) of them about HIV or AIDS and another 40% (12/30) focused on noncommunicable diseases. Our synthesis divided the roles of EHRs into 7 major categories: participant identification and recruitment (12/30, 40%), baseline information collection (6/30, 20%), intervention (8/30, 27%), fidelity assessment (2/30, 7%), primary outcome assessment (24/30, 80%), nonprimary outcome assessment (13/30, 43%), and extended follow-up (2/30, 7%). None of the studies used EHR for participant consent and randomization. Conclusions: Despite the enormous potential of EHRs to increase the effectiveness and efficiency of conducting clinical trials in LMICs, challenges remain. Continued exploration of the appropriate uses of EHRs by navigating their strengths and limitations to ensure fitness for use is necessary to better understand the most optimal uses of EHRs for conducting clinical trials in LMICs.

6 March 2023 in JMIR Preprints
Verified
Preprint
Open access
JYJiancheng Ye
Jiancheng Ye
SXShangzhi Xiong
Shangzhi Xiong
TWTengyi Wang
Tengyi Wang
JLJingyi Li
Jingyi Li
NCNan Cheng
Nan Cheng
YYYang Yang
Yang Yang
BACKGROUND Clinical trials are a crucial element in advancing medical knowledge and developing new treatments by establishing the evidence base for safety and therapeutic efficacy. However, the success of these trials depends on various factors, including trial design, project planning, research staff training, and adequate sample size. It is also crucial to recruit participants efficiently and retain them throughout the trial to ensure timely completion. OBJECTIVE There is an increasing interest in using electronic health records (EHRs)—a widely adopted tool in clinical practice—for clinical trials. This scoping review aims to understand the use of EHR in supporting the conduct of clinical trials in low- and middle-income countries (LMICs) and to identify its strengths and limitations. METHODS A comprehensive search was performed using 5 databases: MEDLINE, Embase, Scopus, Cochrane Library, and the Cumulative Index to Nursing and Allied Health Literature. We followed the latest version of the PRISMA-ScR (Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews) guideline to conduct this review. We included clinical trials that used EHR at any step, conducted a narrative synthesis of the included studies, and mapped the roles of EHRs into the life cycle of a clinical trial. RESULTS A total of 30 studies met the inclusion criteria: 13 were randomized controlled trials, 3 were cluster randomized controlled trials, 12 were quasi-experimental studies, and 2 were feasibility pilot studies. Most of the studies addressed infectious diseases (15/30, 50%), with 80% (12/15) of them about HIV or AIDS and another 40% (12/30) focused on noncommunicable diseases. Our synthesis divided the roles of EHRs into 7 major categories: participant identification and recruitment (12/30, 40%), baseline information collection (6/30, 20%), intervention (8/30, 27%), fidelity assessment (2/30, 7%), primary outcome assessment (24/30, 80%), nonprimary outcome assessment (13/30, 43%), and extended follow-up (2/30, 7%). None of the studies used EHR for participant consent and randomization. CONCLUSIONS Despite the enormous potential of EHRs to increase the effectiveness and efficiency of conducting clinical trials in LMICs, challenges remain. Continued exploration of the appropriate uses of EHRs by navigating their strengths and limitations to ensure fitness for use is necessary to better understand the most optimal uses of EHRs for conducting clinical trials in LMICs.

2 March 2026 in Nutrition & Diabetes
Verified
Journal Article
Open access
TWTengyi Wang
Tengyi Wang
YXYuze Xin
Yuze Xin
XLXinyan Liu
Xinyan Liu
PYPengpeng Ye
Pengpeng Ye
SPShuangjie Peng
Shuangjie Peng
MTMaoyi Tian
Maoyi Tian
China's rapid economic development and urbanisation have led to significant shifts in dietary habits, moving from home-cooked meals to ready foods. This transition may exacerbate the burden of non-communicable diseases. This study aimed to (i) assess the overall nutritional quality and quantities of specific nutrients of ready foods available from Chinese online stores, (ii) evaluate whether these foods comply with national dietary recommendations, and (iii) determine whether the nutritional quality of ready foods differs across manufacturers. This cross-sectional study analysed ready foods from four major Chinese online stores: Taobao, JD.com, Suning, and Vipshop. Ready foods include pre-packaged, partially processed foods requiring minimal cooking or reheating before consumption. The nutritional quality was calculated based on the amount of dietary fibre, saturated fat, protein, sugar, sodium, and energy of the product by using the Health Star Rating (HSR) scoring algorithm. Continuous and categorical variables are described using means (standard deviation [SD]) or median (inter-quartile range [IQR]) and proportions respectively. We identified 109 419 products from the four major online stores, with 2 087 products included in analyses after conducting eligibility checks and removing duplicates. Median nutritional values for all ready foods were as follows: energy content 2203.3 kJ (IQR 2055.6-3222.5), protein content 29.2 g (IQR 14.9-51.5), fat content 35.5 g (IQR 17.0-57.4), carbohydrate content 15.5 g (IQR 5.8-45.6), and sodium content 1733.6 mg (IQR 995.7-3287.1). Only 25.3% of products met the estimated energy recommended range according to the Chinese dietary reference intakes and more than 85.6% exceeded the recommended sodium intake according to Chinese dietary guidelines. The mean HSR was 2.7 (SD = 0.9), and less than half (32.9%) were classified as healthy products (HSR ≥ 3.5). Many of the assessed Chinese ready foods failed to meet national dietary recommendations for nutrient composition and exhibited overall low overall nutritional quality. Potential strategies to combat the growing burden of diet-related non-communicable diseases include (i) enhancing consumer awareness about the nutritional aspects of ready foods, (ii) encouraging the food industry to reformulate products, and (iii) supporting consumers to choose healthier options.